Ginkgo Bioworks Holdings, Inc., a biotechnology company based in Boston, Massachusetts, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on February 29, 2024. The filing, under Form S-8, pertains to the registration of additional shares for the company's 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan. Specifically, the company is registering an additional 85,559,713 shares of Class A and Class B common stock under the 2021 Incentive Award Plan, and 21,389,928 shares of Class A and Class B common stock under the 2021 Employee Stock Purchase Plan. These shares are part of an automatic increase in the number of shares reserved for issuance under the plans for the fiscal year 2024. The shares can be issued in either Class A or Class B form, with each class being convertible to the other on a one-for-one basis. The registration incorporates by reference the contents of the company's previous registration statements filed in 2021 and 2023.

Ginkgo Bioworks Holdings, Inc., a biotechnology company based in Boston, Massachusetts, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on February 29, 2024. The filing, under Form S-8, pertains to the registration of additional shares for the company's 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan. Specifically, the company is registering an additional 85,559,713 shares of Class A and Class B common stock under the 2021 Incentive Award Plan, and 21,389,928 shares of Class A and Class B common stock under the 2021 Employee Stock Purchase Plan. These shares are part of an automatic increase in the number of shares reserved for issuance under the plans for the fiscal year 2024. The shares can be issued in either Class A or Class B form, with each class being convertible to the other on a one-for-one basis. The registration incorporates by reference the contents of the company's previous registration statements filed in 2021 and 2023.